Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that on December 24, 2014 it closed its previously announced registered public offering.
from The Medical News http://ift.tt/1tg5rwG
from The Medical News http://ift.tt/1tg5rwG
No comments:
Post a Comment